acrylamide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on pancreatic cancer incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“We observed no association between dietary acrylamide intake and pancreatic cancer (Table 2).”
Quoted verbatim from Dietary Acrylamide Intake and the Risk of Pancreatic Cancer: The Japan Public Health Center-Based Prospective Study.. - Study
- cohort
- Population
- 89,729 Japanese men and women aged 45-74 years without prior cancer (JPHC Study), energy-adjusted dietary acrylamide intake by quartile, mean follow-up 15.2 years; whole-cohort result
Dietary Acrylamide Intake and the Risk of Pancreatic Cancer: The Japan Public Health Center-Based Prospective Study.2020PMID:33266487Permalink
Keep reading
- Everything the graph holds on acrylamide
- Every compound studied against Pancreatic cancer incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45T49ZHQPDE3G5BCJS8G498